Phathom Pharmaceuticals Reports Q3 2026 Results with EPS Beat and Significant Revenue Growth
Phathom Pharmaceuticals reported third-quarter financial results featuring a Non-GAAP earnings per share (EPS) of $0.04, exceeding analyst expectations by $0.01. While revenue reached $84.7 million—representing a substantial 71.1% increase year-over-year—it narrowly missed consensus estimates by approximately $0.12 million. The company maintains a strong liquidity position with $184.6 million in cash and cash equivalents as of September 30, 2026. Looking ahead, Phathom reaffirmed its full-year 2026 net revenue guidance in the range of $310 million to $325 million, aligning closely with market consensus expectations.
Tickers: $PHAT
Topics: cash position earnings beat financial guidance revenue miss